SINGAPORE (May 15): Net profit of catalist-listed pharmaceutical distributor Hyphens Pharma soared 48.6% to $2.1 million in 1Q20 ended March, from the $1.4 million logged a year ago.

On a fully diluted basis, this translates to earnings per share (EPS) of 71 cents, from 48 cents before. At this level, Hyphens Pharma’s net asset value was 15.26 cents a share, against 14.67 cents as at Dec 31.

The board says it will reclassify its proposed final dividend announced for FY19, as an interim dividend following a delay in payout due to Covid-19. Shareholders can expect to receive a payout of 1 cent a share on Jun 8, the company said in a regulatory filing on May 11.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook